Trending News

#Business #Cell therapy #Oncology #Solid tumours #Turnstone Biologics

Turnstone Biologics reduces employee headcount by 60%

Turnstone Biologics has announced a “strategic prioritisation of its pipeline”, as well as a workforce reduction of approximately 60% and changes to its leadership team. The cuts are designed to allow the company to focus resources on the continued advancement of its Phase I programme, selected tumour-infiltrating lymphocyte (TIL) therapy… Read More

#Business & Investment #News #Trending News

Neurons
#Bipolar #Neuroscience #Psychiatry #Society for Neuroscience #Walsh Research Institute

Breakthroughs in bipolar disorder announced at Neuroscience 2024

A Walsh Research Institute scientist presented an advanced theory of bipolar disorder at the annual meeting of the Society for Neuroscience, Neuroscience 2024. After a multi-year investigation of recent neuroscience advances, Dr William Walsh believes he has resolved many unknowns that have puzzled researchers for a… Read More

#News #Trending News

Pluripotent stem cells
#Cell therapy #Neuroscience #Pluripotent stem cells #Society for Neuroscience #Stem cells

Neuroscience 2024: Leveraging human stem cells to treat diseases

Progress in stem cell technologies is advancing powerful new ways of studying and treating formerly intractable neurological and neuropsychiatric diseases. Several interwoven examples have been discussed at Neuroscience 2024, the annual meeting of the Society for Neuroscience. Over 40% of the global population lives with some… Read More

#News #Trending News

Ozempic Insulin injection pen
#Diabetes #GLP-1 #Neuroscience #Obesity #Society for Neuroscience #Weight loss

News from SfN’s Neuroscience 2024: The brain on GLP-1 agonists

Diabetes and weight loss drugs known as glucagon-like peptide-1 (GLP-1) receptor agonists have widespread effects in the brain, with new research presented at the Society for Neuroscience’s Neuroscience 2024 uncovering potential novel therapeutic benefits and behavioural side effects. About one in eight adults… Read More

#News #Trending News

Doctor prepares vaccine
#Clinical trials #Immunology / Virology & Vaccines #Marburg virus #Vaccine candidate #World Health Organization

Vaccine trials to start in response to Marburg virus outbreak

Rwanda will start clinical trials of experimental vaccines and treatments for Marburg virus in the next few weeks, its health minister announced following news of an outbreak in the country. Marburg virus disease is highly virulent and causes haemorrhagic fever, with a fatality ratio of up… Read More

#News #Trending News

Antibiotics
#ABPI #Antibiotics #Antimicrobial resistance (AMR) #Antivirals #United Nations #WHO

Access to medicines vital in tackling AMR, world leaders agree

Global leaders have approved a plan to reduce the estimated 4.95 million human deaths associated with bacterial antimicrobial resistance (AMR) annually by 10% by 2030. The political declaration was agreed at the 79th United Nations General Assembly (UNGA) High-Level Meeting on Antimicrobial Resistance (AMR). Read More

#News #Trending News

Brain inflammation
#Bristol Myers Squibb #FDA #Neuroscience #PureTech #Schizophrenia

New approach to schizophrenia treatment secures US approval

The US Food and Drug Administration (FDA) has approved Cobenfy (xanomeline and trospium chloride) capsules for the treatment of schizophrenia in adults. It is the first antipsychotic drug approved to treat schizophrenia that targets cholinergic receptors as opposed to dopamine receptors, which has long been the standard of care. “Schizophrenia… Read More

#News #Regulatory #Trending News

Monoclonal antibody
#ESMO #Innovent #Monoclonal antibodies #Oncology #Solid tumours

Innovent updates ESMO 2024 on mAbs in solid tumours

Innovent Biologics revealed clinical data on two of its mAb (monoclonal antibody) programmes at the 2024 ESMO Congress. In a Phase I/II study in advanced solid tumours, IBI354 (HER2 monoclonal antibody-camptothecin derivative conjugate) has demonstrated an excellent safety profile. A total of 368 participants… Read More

#News #Trending News

Genomics
#Cancer drug targets #Gene mutation #Genetics / genomics #Oncology #Wellcome Sanger Institute

‘Cancer-protection’ gene study reveals potential cancer drug targets

Scientists have pinpointed thousands of genetic changes in a gene that may increase a person’s risk of developing breast and ovarian cancer and also identified new potential therapeutic targets. Researchers from the Wellcome Sanger Institute and their collaborators focused on the ‘cancer protection’ gene RAD51C, known… Read More

#Cancer Research #News #Trending News

Cancer metastasis
#Cancer therapeutics #Clinical trials #ESMO #Events #Oncology

The latest breakthroughs in cancer research

The European Society for Medical Oncology (ESMO) Congress 2024 took place in Barcelona, Spain, 13-17 September 2024, and featured some significant breakthroughs in cancer drug discovery. NIAGARA Phase III trial AstraZeneca presented positive results from its NIAGARA Phase III trial, a global study to evaluate the… Read More

#Cancer Research #News #Trending News

X-ray showing colon cancer
#Colorectal cancer #Janssen #Monoclonal antibodies #Oncology #Phase II trial

Metastatic colon cancer: 49% response for combination therapy

Janssen-Cilag has shared new data from the Phase Ib/II OrigAMI-1 study at the European Society of Medical Oncology (ESMO) 2024 Congress. The results show that amivantamab combined with chemotherapy demonstrated promising antitumour activity in patients with RAS/BRAF wild-type (WT) metastatic colorectal cancer (mCRC) who have not… Read More

#Cancer Research #News #Trending News

Tau proteins
#Alzheimer's #Neurodegenerative disorders #Tau protein #University of Cambridge

New therapy targets and destroys tau tangles in Alzheimer’s

Scientists have developed two new potential therapies that selectively remove aggregated tau proteins, which are associated with Alzheimer’s disease, and improve symptoms of neurodegeneration in mice. They say this promising approach could also be applied in future to other brain disorders driven by protein aggregation inside… Read More

#News #Trending News

Obese man measures his waist
#European Association for the Study of Diabetes #GLP-1 #Obesity #Phase I trial #QL Biopharm

QL Biopharm announces new obesity drug results

QL Biopharm, a clinical stage biopharmaceutical company developing biologic drugs for the treatment of metabolic diseases, has shared Phase Ic clinical data for its lead drug candidate ZT002. The data was presented at the European Association for the Study of Diabetes (EASD) Annual Meeting 2024, Madrid,… Read More

#News #Trending News

Human eye
#Gene therapy #Genetics / genomics #Ophthalmology #Rare disease #University of Florida

Gene therapy restores vision in first-of-its-kind trial

A gene therapy developed by University of Florida scientists restored useful vision to most patients with rare condition Leber congenital amaurosis type I (LCA1) in a small trial. Patients who received the highest dose of the gene therapy saw up to a 10,000-fold improvement in their… Read More

#News #Trending News